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Abstract
We demonstrated previously that the incorporation of a membrane-anchored form of flagellin into influenza virus-like
particles (VLPs) improved the immunogenicity of VLPs significantly, inducing partially protective heterosubtypic immunity
by intramuscular immunization. Because the efficacy of mucosal vaccination is highly dependent on an adjuvant, and is
particularly effective for preventing mucosal infections such as influenza, we determined whether the membrane-anchored
flagellin is an efficient adjuvant for VLP vaccines by a mucosal immunization route. We compared the adjuvant effect of
membrane-anchored and soluble flagellins for immunization with influenza A/PR8 (H1N1) VLPs by the intranasal route in a
mouse model. The results demonstrate that membrane-anchored flagellin is an effective adjuvant for intranasal (IN)
immunization, inducing enhanced systemic and mucosal antibody responses. High cellular responses were also observed as
shown by cytokine production in splenocyte cultures when stimulated with viral antigens. All mice immunized with
flagellin-containing VLPs survived challenge with a high lethal dose of homologous virus as well as a high dose
heterosubtypic virus challenge (40 LD50 of A/Philippines/82, H3N2). In contrast, no protection was observed with a standard
HA/M1 VLP group upon heterosubtypic challenge. Soluble flagellin exhibited a moderate adjuvant effect when co-
administered with VLPs by the mucosal route, as indicated by enhanced systemic and mucosal responses and partial
heterosubtypic protection. The membrane-anchored form of flagellin incorporated together with antigen into influenza
VLPs is effective as an adjuvant by the mucosal route and unlike standard VLPs, immunization with such chimeric VLPs elicits
protective immunity to challenge with a distantly related influenza A virus.
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Introduction
Although most infectious pathogens enter through mucosal
surfaces [1] traditional immunization strategies, including the
parenteral route, do not induce effective mucosal responses [2,3].
IN immunization has been shown to be effective for protection
against infectious respiratory diseases such as influenza [4,5].
Although there are attractive advantages of mucosal immunization
over traditional injection routes, few of the current vaccines that
are approved for human use are administered mucosally [6].
Often the effectiveness of mucosal immunization depends on co-
administration of appropriate adjuvants that can initiate and
support the transition from innate to adaptive immunity [7].
Mucosal adjuvants are required not only to boost mucosal and
systemic immunity, but also to prevent the induction of mucosally
induced tolerance [6]. Enterotoxins, including cholera toxin (CT)
and heat-labile toxin (LT), have been very effective mucosal
adjuvants experimentally, but their toxicity limits their use in
humans [8]. Finding alternative mucosal adjuvants is therefore of
high priority for the development of mucosal vaccines. The use of
particulate antigens and adjuvants has been evaluated by several
groups and found to be advantageous for mucosal immunization
[9,10]. Such particles (e.g., microparticles, virosomes, and virus-
like particles [VLPs]) have comparable dimensions to pathogens
that the immune system evolved to combat, and therefore are
naturally targeted for uptake by antigen-presenting cells (APCs) to
facilitate the induction of potent immune responses [11].
Influenza viruses are able to evade the host immune system
since they continuously undergo antigenic evolution through the
process of drift and shift [12]. Furthermore, poultry and migratory
birds are reservoirs for new emerging influenza viruses which may
cause pandemics in humans [13]. Although vaccination is the most
effective approach to prevent influenza [14,15], current influenza
vaccines are highly strain-specific. Protection offered by the
current inactivated influenza vaccines is mainly based on the
induction of neutralizing antibodies against the surface protein
hemagglutinin (HA). Novel influenza vaccines that induce a
greater breadth of immunity may overcome limitations in vaccine
efficacy in combating the antigenic variability of influenza A
viruses [5].
Flagellin is the primary protein component of the highly
complex flagellar structures that extend from the outer membranes
of Gram-negative organisms. Flagellin has been shown to be
recognized by TLR5, a member of the Toll-like receptor (TLR)
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13972families on mammalian cell surfaces [16]. Acting as the natural
agonist of TLR5, flagellin is a strong inducer of innate immune
effectors such as cytokines and nitric oxide [17,18] and is a potent
and effective adjuvant [19,20]. Because mucosal immunization
offers many attractive features compared with other routes in
prevention of mucosal infection, and influenza VLPs are a potent
new generation of vaccines, we determined whether mucosal
immunization with influenza VLPs containing membrane-bound
flagellin induces enhanced immune responses, including mucosal
and systemic responses with broad reactivity.
Results
IN immunization with flagellin-containing influenza VLPs
induces strong mucosal responses
It is well recognized that mucosal immune responses are
effective for protection against diseases initiated by mucosal
surface infection [21]. These immune responses are most
efficiently induced by the direct application of vaccines onto
mucosal surfaces, and are enhanced by co-administered adjuvants
[6,22]. To determine whether membrane-anchored flagellin
functions as a mucosal adjuvant and induces enhanced mucosal
antigen-specific responses when incorporated into influenza VLPs,
mice were immunized IN with defined doses of standard influenza
VLPs (HA/M1 VLPs), chimeric VLPs (HA/FliC/M1 cVLPs), a
mixture of standard VLPs with recombinant soluble flagellin (HA/
M1 VLPs + sFliC), or M1 VLPs (Table 1), as described in
Materials and Methods. The flagellin-containing VLP-immunized
mice showed IgA (Fig. 1A) and IgG (Fig. 1B) titers of 4.3610
4 and
1.6610
4 in the lung lavage, which were 5.7- and 13-fold higher
than those of the standard VLP group (7.5610
3 and 1.2610
3
respectively). Although the IgA and IgG levels in nasal and
tracheal washes were lower compared to those in mouse lung
lavage, the membrane-anchored flagellin-containing VLP-immu-
nized group showed about 6.4-fold higher IgA levels in both nasal
and tracheal washes (8.3610
3), and 2.8- and 4-fold higher IgG
levels in nasal (2.6610
3) and tracheal (3.6610
3) washes compared
to those of mice immunized by standard influenza VLPs.
Recombinant soluble flagellin also showed a mucosal adjuvant
effect when co-administered with influenza VLPs but its activity
was lower than that of the membrane-anchored form. As shown in
Fig. 1A, the IgA levels in the lung lavage, nasal and tracheal
washes of mice immunized with the mixture of recombinant
flagellin and standard VLPs were lower than those observed with
flagellin-containing VLPs but were higher than those of standard VLP-immunized mice. The IgG titer in the lung lavage of mice
immunized by the mixture of soluble flagellin and standard VLPs
was 3.3610
3, 2.5-fold higher than the standard VLP group, but
the IgG titers in nasal and tracheal washes of these mice did not
show a significant difference from that of the standard VLP group
(Fig. 1B).
To determine whether the mucosal secretions have neutraliza-
tion activity, the ability of these mucosal samples to neutralize live
PR8 virus was evaluated using a MDCK cell-based plaque assay.
As shown in Table 2, the neutralization titers of mice immunized
with VLPs containing membrane-anchored flagellin were 80, 20
and 20 in lung lavage, nasal and tracheal washes, respectively. In
contrast, mice immunized with standard VLPs, or a mixture of
soluble flagellin and standard VLPs, showed a neutralization
activity of 40 in lung lavage, and no activity in nasal or tracheal
washes. We further evaluated whether the mucosal samples
neutralize a heterosubtypic virus, A/Philippines/82 (H3N2), and
found that lung lavage from the cVLP group showed the highest
functional neutralization titer of 20. All other mucosal samples
showed lower or undetectable neutralization titers to the
Figure 1. Mucosal IgA and IgG titers against PR8 virus. Samples
were collected as described in Materials and Methods. Collected
mucosal samples were cleared by a brief centrifugation (8000 rpm for
10 min), and assessed by ELISA. Microtiter plates were coated with
100 ml/well of inactivated PR8 virus (5 mg/ml) and HRP-conjugated goat
anti-mouse IgA or IgG antibodies were used for detection. Antibody
endpoint titers were defined as the highest serum dilution (fold) which
gave an OD450 value 2-fold higher than naı ¨ve mice at the lowest
dilution (2006). Representative data are the geometric mean 6
standard deviation (SD) of six mice per group. Comparisons were
performed using the non-matching two-way ANOVA followed by
Bonferroni’s post test. P,0.05(*), P,0.01(**), P,0.001(***),
P.0.05(n.s.). A, Mucosal IgA titers; B, Mucosal IgG titers. Bars 1, 2, 3
and 4 presented groups of M1 only VLPs, HA/M1VLPs, HA/FliC/M1
cVLPs, and HA/M1VLPs + sFliC, respectively. FliC, flagellin; sFliC, soluble
flagellin.
doi:10.1371/journal.pone.0013972.g001
Table 1. Mouse groups for IN immunization.
Groups* Dose**
VLPs 10 mg VLPs
cVLPs*** 10 mg VLPs
VLPs + sFliC**** 10 mg VLPs+0.5 mg sFliC
M1 only VLPs 10 mg VLPs
*Naı ¨ve mice and a PBS immunized group did not show antigen specific
responses and thus are not presented here.
**Doses were given in a total of 25 ml split between two nostrils.
***The dose of cVLPs was normalized to contain an HA content equal to 10 mg
of standard VLPs by Western Blot. The content of the flagellin protein was
0.5 mg in each dose of cVLPs calculated by using purified recombinant flagellin
as a standard.
****Purified recombinant soluble flagellin (sFliC) was mixed with standard VLPs
before administration.
doi:10.1371/journal.pone.0013972.t001
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anchored flagellin enhances the immunogenicity of VLPs when
immunized mucosally, inducing high levels of mucosal immunity
exhibiting broadened reactivity.
Chimeric VLPs containing membrane-anchored flagellin
elicit high levels of systemic antibody responses by the
IN route
An advantage of mucosal over parenteral immunization is the
ability to induce both systemic and mucosal antigen-specific
responses. To determine if IN immunization with flagellin-
containing influenza cVLPs induced enhanced humoral responses,
the influenza-specific IgG endpoint titers of immune sera were
evaluated. As shown in Fig. 2A, more than 5-fold higher virus-
specific serum IgG levels were observed in mice immunized with
membrane-anchored flagellin-containing cVLPs (3.4610
5) com-
pared with the standard influenza VLP group (6.4610
4). When
recombinant flagellin was mixed and co-administered with
standard VLPs, systemic responses were enhanced but to a lesser
extent than observed with cVLPs. These results indicate that the
membrane-anchored flagellin shows a stronger adjuvant effect
than the soluble form in induction of serum IgG responses.
We also evaluated whether serum antibodies induced by cVLPs
exhibit higher heterosubtypic reactivity. As shown in Fig. 2B, the
serum IgG endpoint titer of the cVLP (HA/FliC/M1) group
specific to Philippines virus (H3N2) was 2-fold higher than that of
the standard VLP group (HA/M1 VLPs). Similar to the
membrane-anchored form, soluble recombinant flagellin also
showed significant enhancement of humoral heterosubtypic
reactivity when co-administered with VLPs (group HA/M1
VLPs+sFliC), with 1.8-fold higher antibody binding to Philippines
than the standard VLPs. These results demonstrate that both the
membrane-anchored flagellin and the soluble form are effective in
inducing enhanced systemic antibody responses exhibiting hetero-
subtypic binding activity.
B lymphocytes can change the isotype and subclass of the
antibody they express by immunoglobulin (Ig) isotype switch
recombination. The Ig isotype profile reflects different mecha-
nisms of antigen presentation and cognate interaction with helper
T cells. To understand how IgG subclasses are affected by the
presence of the membrane-anchored flagellin in VLPs, the serum
PR8-specific IgG subclass endpoint titers of immunized mice were
assessed and compared to those of mice immunized with standard
VLPs, or mixture of standard VLPs and recombinant flagellin. As
shown in Fig. 3, the membrane-anchored flagellin boosted the
production of all subclasses compared to the standard VLP group
with/without soluble recombinant flagellin. In particular, cVLPs
induced high levels of the IgG3 isotype while the standard VLPs or
the mixture of the standard VLPs and recombinant flagellin
showed IgG3 at background levels as shown in Fig. 3D. It is
known that IgG1 and IgG3 subclasses can directly recruit
phagocytic cells to ingest antigen-antibody complexes, as well as
activating the complement system [23]. These results demonstrate
that the membrane-anchored flagellin in cVLPs not only improves
the antibody production quantitatively but also qualitatively
changes the subclasses of antibodies induced, indicating different
activation mechanisms of B cells.
Membrane-anchored flagellin induces serum antibody
responses conferring enhanced hemagglutination
inhibition (HI) and virus neutralization
As described above, cVLPs containing the membrane-anchored
flagellin enhanced both mucosal and systemic antibody responses.
We further determined whether cVLPs induce serum antibodies
with higher neutralizing titer (NT) in a MDCK-based neutraliza-
tion assay. As showed in Fig. 4, the cVLP group showed a NT of
2560, which was 4-fold higher than that of the standard VLP
group (640), demonstrating the adjuvant effect of the membrane-
anchored flagellin for inducing antibodies which are functional in
blocking infection by live virus. In contrast to cVLPs, the mixture
of soluble flagellin and standard VLPs induced a moderately
Table 2. Neutralization activity of mucosal samples using
A/PR8 virus.
Groups Lung lavage Nasal washes Tracheal washes
VLPs 40* ,10 ,10
cVLPs 80 20 20
VLPs + sFliC 40 ,10 ,10
M1 VLPs undetectable undetectable undetectable
*Number represents fold dilution of mucosal samples which induced 50%
plaque reduction. Six mice were included in each group. Data represents means
of six mice.
doi:10.1371/journal.pone.0013972.t002
Figure 2. Serum IgG endpoint titers. Endpoint titers of immune
serum IgG specific to A/PR8 (A) or cross-reactive binding to A/
Philippines (B) were determined using ELISA as described in Materials
and Methods. HRP-conjugated goat anti-mouse IgG antibody was used
for detection. Endpoint titers were defined as in Fig 1. M1, M1 only
VLPs; HA/M1, HA/M1 VLPs; HA/F/M1, HA/flagellin (FliC, F)/M1 cVLPs; HA/
M1+sF, mixture of HA/M1 VLPs plus soluble flagellin (sFliC, sF).
doi:10.1371/journal.pone.0013972.g002
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detectable NT to the A/Philippines virus (data not shown).
For influenza vaccines, the induction of antibodies with
hemagglutination-inhibition (HI) capacity correlates with their
protective efficacy. To further compare the systemic responses
induced, we determined the HI activity of immunized mouse sera
against both A/PR8 and A/Philippines viruses. As shown in
Fig. 5A, the cVLPs group induced HI responses to A/PR8 virus at
a mean titer of 1700, while the responses to the standard VLP
group were 640. The mixture of soluble flagellin with standard
VLPs induced HI titers with a mean value of 850. As shown in
Fig. 5B, cVLPs containing the membrane-anchored flagellin also
induced antibodies showing HI activity to A/Philippines virus (a
mean value of 28). In contrast, both standard VLPs and the
mixture of soluble flagellin with standard VLPs showed HI titers
less than 20. These results further demonstrate that the
membrane-anchored flagellin incorporated together with antigen
in the same VLPs is effective as a mucosal adjuvant.
Figure 3. Endpoint titers of PR8-specific IgG subclasses. IgG subclass endpoint titers were determined as for serum IgG endpoint titer but
using HRP-conjugated goat anti-mouse IgG1(A), IgG2a (B), IgG2b (C) or IgG3 (D) for detection.
doi:10.1371/journal.pone.0013972.g003
Figure 4. Neutralization activity against PR8. Immune sera were
diluted 2-fold stepwise and incubated with virus (100 PFU) at 37uC for
1 h. A standard plaque reduction assay was performed using MDCK cell
cultures.
doi:10.1371/journal.pone.0013972.g004
Figure 5. Hemagglutination inhibition (HI) titers against H1N1
PR8 or H3N2 Philippines virus. A, HI titers to PR8 virus; B, HI titers
to Philippines virus. HI titers of immune sera were determined as the
capacity of sera to inhibit virus hemagglutination of chicken red blood
cells. Representative data are the geometric mean 6 S.D.
doi:10.1371/journal.pone.0013972.g005
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T cell responses
Antigen-specific T lymphocytes are important for the genera-
tion and regulation of an effective immune response. Cytokines
produced by T cells upon antigen stimulation have a central role
in these processes. To determine whether membrane-anchored
flagellin-containing VLPs induce different cytokine patterns, which
may up-regulate antigen-specific immune responses, INF-c or IL-
4-producing T lymphocyte splenocyte populations were evaluated
using ELISpot assays. As shown in Fig. 6, cVLP-immunized mice
had the highest INF-c and IL-4 producing populations compared
to other groups when stimulated with MHC I or II-restricted PR8
HA peptide pools, revealing both high antigen-specific Th1 and
Th2 subpopulations of helper T cells (CD4+). Soluble flagellin,
used in the same amount, induced a weak enhancement of the
INF-c producing population as shown in Fig.6A and a moderate
enhancement of the IL-4 producing population (Fig. 6B). These
results demonstrate that membrane-anchored flagellin enhances
the magnitude of cellular responses to influenza VLPs.
Membrane-anchored flagellin enhances heterosubtypic
protection against lethal virus challenge
To determine whether the enhanced immune responses which
we observed with cVLPs correlate with protective efficacy against
virus infection, immunized mice were challenged with lethal doses
of the homologous H1N1 PR8 virus (40 LD50) or the
heterosubtypic H3N2 Philippines virus (40 LD50). For PR8 virus
challenge, all mice were protected by VLP immunization except
for the M1 VLP group (Fig. 7A) as expected. Also, no clinical sign
of illness was observed as monitored by mouse body weight change
(Fig.7B), demonstrating the efficacy of HA-containing VLPs in
inducing protective immunity to the homologous virus. However,
the standard influenza VLPs did not provide protection against the
heterosubtypic virus. All mice infected with Philippines virus (40
LD50) reached their endpoint (25% of body-weight loss), as
observed with the M1 only VLP group (Fig. 7C). The mixture of
standard influenza VLPs with soluble flagellin provided partial
protection, demonstrated by survival of 4 of 6 mice (67%) and
22% body-weight loss. In contrast, the membrane-anchored
flagellin-containing VLPs provided 100% protection to the
Philippines virus challenge (Fig. 7C), and only a moderate weight
loss was observed (Fig. 7D). These results indicate that flagellin
together with antigen in the same particulate structure functions
better as a mucosal adjuvant as shown by the increased breadth of
protective immunity.
Lung viral loads are important measures of decreased morbidity
and mortality after infection. Thus we determined the virus loads
at day 4 in the lungs of immunized mice after challenge infection
with PR8 or Philippines viruses. As shown in Fig. 8, all HA-
containing VLPs were effective in clearance of PR8 virus,
indicated by undetectable lung virus titers on day 4 in comparison
to the high virus load of the control group (M1 only VLP group,
8.4610
8 PFU/lung). For A/Philippines virus-infected mice, the
standard VLP group showed a virus titer of 3610
5 PFU/lung,
whereas the cVLP group showed 60-fold lower titers of 5610
3.
The mixture of standard VLP with soluble flagellin was
4610
4 PFU/lung, 8-fold lower than the standard VLP group.
Thus, IN immunization with influenza cVLPs is more effective at
inducing protective immunity against a heterosubtypic virus
challenge.
Discussion
VLPs have been tested as mucosal vaccines to induce protective
immunity against mucosally transmitted infectious diseases
[24,25]. Because of the advantages of mucosal immunization
and the enhancement of the mucosal immune responses by
adjuvants [21], it was of high interest to determine whether a
membrane-anchored TLR agonist can function as mucosal
adjuvant when incorporated into VLPs. The current studies were
therefore designed to determine the responses to chimeric flagellin-
containing VLPs as influenza vaccines using an IN immunization
route. An important characteristic of the mucosal adaptive
immune responses is the local production and secretion of dimeric
or multimeric IgA antibodies that are resistant to degradation in
the protease-rich mucosal environment[26]. Our results show that
influenza cVLPs incorporating flagellin induced high levels of IgA
and IgG secretion and enhanced mucosal virus neutralization
activity against homo- or heterosubtypic viruses compared with
standard VLPs or a mixture of standard VLPs with soluble
flagellin. The same amount of flagellin in soluble form showed a
detectable but reduced adjuvant effect in boosting mucosal IgA
secretion, suggesting that different mechanisms may be involved in
sensing these two different forms. It is known that APCs can be
Figure 6. Cytokine secretion from immunized mouse spleno-
cytes. ELIspot assays were used to detect the proliferation of antigen-
specific CD4+ secreting INF-c (A) or IL-4 (B) cells as described in
‘‘Materials and Methods’’. Splenocytes were isolated from immunized
mice 4 weeks after the boosting immunization and seeded into pre-
coated Multiscreen plates (Millipore). Defined peptides (MHC I or MHC
II) or inactivated PR8 viruses were added to stimulate antigen-specific T
cell proliferation. Cytokine secreting clones were visualized by spot
staining following the manufacturer’s instruction. Representative data
were mean 6 S.D. of spot number in 1610
6 splenocytes of six mice.
doi:10.1371/journal.pone.0013972.g006
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the direction of the induced immune responses. The upper
respiratory tract (nasal-associated lymphoid tissue, NALT) con-
tains an abundance of APCs, in particular mucosal DCs,
expressing TLR molecules on their surfaces [2,27]. Flagellin in
cVLPs binds to TLR5 and thus not only can initiate innate
signaling to secrete cytokines and upregulate other immune cells
but also may facilitate DCs to ingest antigens and then present
them to helper T cells [11,28]. In contrast, co-administered soluble
flagellin may target different DCs from those which encounter
VLP antigens. The incorporation of membrane-anchored flagellin
into the VLPs ensures that the antigen and adjuvant are delivered
to the same cells, which may provide the basis for the much higher
adjuvant effects of the flagellin incorporated in VLPs compared
with the soluble form when used in the same amount.
An effective mucosal vaccine should induce both mucosal and
systemic immune responses. Our results show that the membrane-
anchored flagellin-containing VLPs induce enhanced antigen-
specific systemic immunity. This enhancement was illustrated by
higher levels of serum antibody titers with improved neutralization
activity and HI titers. Increased systemic responses have been
reported to be promoted by different forms of flagellin when
mucosally administered, including polymeric, recombinant solu-
ble, or fusion proteins and truncated flagellins [20,29,30]. A
notable finding in our study was that the membrane-anchored
flagellin co-incorporated with antigen into VLPs was more
effective in inducing more broadly reactive antibody responses
compared to soluble recombinant flagellin. Although soluble
flagellin also induced enhanced antibody responses (HAI titers) to
the homologous H1 virus when compared to standard VLPs, the
enhancement of HAI titers to a heterologous H3 virus was not
significant. These results suggest that membrane-anchored
flagellin is more effective in boosting responses directed against
cross-reactive determinants shared in HA molecules of distantly
related heterosubtypic strains. Since the HAI titer is known to be
correlated with protection in influenza vaccination, these results
also support the conclusion that the enhanced antibody responses
contribute to the observed cross-protection. We found previously
that membrane-anchored flagellin enhanced immunity and
conferred partial heterosubtypic cross-protection by intramuscular
immunization [31]. The present data show that cVLPs containing
flagellin are able to confer complete heterosubtypic protection by
Figure 7. Live virus challenge using A/PR8 (H1N1) or A/Philippines (H3N2) viruses. Immunized mice were challenged with a lethal dose (40
LD50) of A/PR8 (A and B) or A/Philippines (C and D) in a volume of 25 ml by IN instillation. Mouse survival (A, C) and body weight changes (B, D) were
monitored daily.
doi:10.1371/journal.pone.0013972.g007
Figure 8. Lung viral loads on day 4 post-challenge infection
with the homologous virus A/PR8 or the heterosubtypic virus
A/Philippines. Mice immunized IN with designed doses of VLPs were
challenged with a lethal dose (40 LD50) of A/PR8 or A/Philippines. Six
mice were included in each viral challenge group. Four days after
infection, mouse lungs were collected and extracted with medium RPMI
1640. The extract was adjusted to 1 ml per lung. Virus titers in lung
extracts were titrated using MDCK-based plaque assay as described in
Materials and Methods. The lung virus titer is presented as pfu per lung.
doi:10.1371/journal.pone.0013972.g008
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VLPs as mucosal adjuvant has great potential for developing
broadly cross-reactive influenza vaccines.
A potentially new pandemic influenza virus, and particularly a
highly pathogenic strain of a novel subtype, will likely allow little
time for the development and production of a traditional strain-
specific vaccine. Increased breadth of immunity with cross-
protection against drifted and even shifted strains has long been
pursued in the development of influenza vaccines because of the
potential to prevent epidemics and possible pandemics [32,33].
Although there is high genetic diversity of the HA peptides
between the different subtypes, certain regions of the HA
molecules of antigenically different subtypes show considerable
sequence homologies which are attributed to the need for
conservation of function and structural requirements, in particular
in the HA2 portion and more deeply located regions of the HA1.
An overall conservation of 33–36% of amino acid sequences
between HAs has been reported [34]. PR8/34(H1N1, HA
sequence access no. AA67033) and Philippines/2/82 (H3N2,
AH sequence access no. ABQ58936.1) share 34% amino acids
in their peptides when compared using MegAlign 7 (DNASTAR
Inc., Madison, WI). Such similarity in the HA molecules could
provide a basis for the observed cross-protection. Several strategies
have been used to confer enhanced protection including the use of
adjuvants [35,36,37]. With inactivated vaccines the most effective
cross-protective immunity was achieved by IN delivery with
adjuvants [5,38,39]. The results in the present study indicate that
besides providing enhanced immunity against the homologous
subtype, cVLPs containing the membrane-anchored flagellin
induce protective immunity against heterosubtypic challenge
when a H3N2 virus was used, whereas standard influenza VLPs
did not confer any detectable heterosubtypic protection. Although
a significant role of cellular immune responses in providing
heterosubtypic protection has been reported with adjuvanted
inactivated viruses or cold-adapted live virus vaccines [5,37,39],
cell-mediated immunity may not be an important effector in
heterosubtypic responses induced by our chimeric VLPs because
few shared T cell epitopes are found in their HA and M1 protein
components. However, significantly enhanced cellular immune
responses against homologous antigens were induced by IN
delivery of flagellin-containing VLPs as demonstrated by the recall
of antigen-specific cytokine release, in particular INF-c produc-
tion, by splenocytes from immunized mice. INF-c stimulates the
expression of both MHC I and II molecules and co-stimulatory
molecules on APCs, and promotes the differentiation of naı ¨ve
helper T cells into Th1-biasing immunity CTL responses [40].
Although nonspecific cells including NK cells and nonlymphoid
cell types such as macrophages in raw splenocytes are potential
sources of cytokines, these cell types may not contribute to antigen-
specific cytokine production. These observations demonstrate that
mucosal delivery of cVLPs containing flagellin enhances both
humoral and cellular immune responses and thus may therefore
present a valuable approach in controlling new influenza
epidemics and pandemics.
A broadly cross-protective influenza vaccine would have at least
two potential advantages. One of these is to increase the breadth of
immunity against new seasonal variants (drift strains), thus
reducing the need for annual revaccination. Because of recent
concerns about vaccine adjuvants, and the variable impact of such
seasonal variants, the flagellin-containing VLPs may not be
accepted for such use at least in some countries, although we
did not observed any symptoms of illness when a dose 0.5 mg
flagellin per mouse was used by IN immunization. A second major
advantage of a broadly cross-protective influenza vaccine is to
control a newly emerging pandemic strain, against which the
population has no immunity. Such a vaccine could be produced in
advance, and be rapidly deployed to limit the spread and the
disease severity resulting from a new pandemic virus. In the event
that such a pandemic virus strain causes a highly lethal human
infection, such as those caused by avian H5N1 viruses, the rapid
deployment of an adjuvant-containing VLP vaccine could have a
major impact on reducing morbidity and mortality.
Materials and Methods
Ethics Statement
Mice were sterile housed and treated according to Emory
University (Atlanta, GA) guidelines and all animal studies were
approved by the Emory University Institutional Animal Care and
Use Committee. Emory University’s Animal Welfare Assurance
number is A3180-01.
Cell lines and viruses
Spodoptera frugiperda Sf9 cells (Sf9, ATCC, CRL-1711) and
Madin-Darby canine kidney (MDCK, ATCC, CCL-34) cells were
cultured as described previously [31]. Influenza viruses A/PR8/34
(H1N1) and A/Philippines/2/82 (H3N2) were grown in 10-day-
old embryonated hen’s eggs and purified from allantoic fluid by
using a discontinuous sucrose gradient (15%, 35%, and 60%) [39].
Inactivation of the purified viruses was performed by adding
formalin to a final concentration of 1:4000 (v/v) as described
[41,42]. Mouse-adapted PR8 and Philippines viruses were
prepared as lung homogenates from intranasally infected mice as
described [39]. The mouse-adapted viruses were titrated by
infection of mice with various dilution, and the LD50 was
calculated by the method of Reed and Muench [43].
VLP production and characterization
Recombinant baculoviruses (rBVs) and VLPs were produced as
described [31]. In brief, rBVs expressing PR8 HA, flagellin (FliC),
or M1 were propagated in Sf9 cell culture, and their titers were
determined by plaque assay. Standard influenza VLPs (HA/M1
VLPs) and flagellin-containing influenza chimeric VLPs (HA/
FliC/M1 cVLPs), as well as VLPs containing M1 only, were
produced by co-infection of Sf9 cells with recombinant baculo-
viruses expressing HA and M1, FliC, HA and M1, or M1 only,
respectively. For cVLPs, the MOIs of rBV expressing HA, M1 and
FliC were adjusted to 2:6:3 to produce cVLPs containing 5%
flagellin. The quality of purified VLPs was determined by Western
blotting analysis, hemagglutination activity analysis, and electron
microscopic observation [31]. The sterility was determined by
inoculation into LB and culturing at 37uC for 48 h. The flagellin
content in cVLPs was evaluated using ELISA as described [31].
Mouse IN immunization
Inbred female BALB/c mice were obtained from Charles River
Laboratory. Six-mouse groups were IN immunized twice at 4-
week intervals (weeks 1 and 5). To perform IN immunization, mice
were lightly anesthetized by inhalation of isofluorane and a total of
25 ml containing defined doses of VLPs and flagellin (Table 1) was
instilled into the nostrils. VLP concentrations of 10 mg were used
because previous studies have shown that this dose can induce
protective immunity [31,44]. We found that mice were more
sensitive to flagellin by the IN immunization, therefore 0.5 mg
flagellin was used in the IN immunization compared to 0.8 mg
flagellin used in previous experiments for intramuscular immuni-
zation [31].
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Blood samples were collected by retro-orbital plexus puncture.
Sera were collected by a brief spin (5000 rpm for 5 min) after
clotting (about 1 hour at room temperature) one week before
immunization (pre-immune sera, week 0) and 4 weeks after the
boosting immunization (immune sera, week 9) respectively.
Mucosal samples were collected at week 9. Nasal washes were
collected by lavaging mouse nostrils repetitively with 250 ml PBS
containing 0.05% Tween 20 (PBST). For tracheal washes, trachea
from immunized mice were soaked in 250 ml PBST overnight. To
collect lung lavage, individual mouse lungs were lavaged
repetitively with 1 ml PBS. After a brief centrifugation
(8000 rpm) for 10 min, supernatants were filtered through a
0.22 mm filter and stored at 280uC for further assays.
Live virus challenge
Immunized mice were challenged with mouse-adapted PR8
H1N1 or Philippines H3N2 viruses 4 weeks after the boosting
immunization (week 9). A dose of 40 LD50 (equal to 2000
infectious particles for PR8 and 1000 for Philippines) was used for
challenge infection. Mice were lightly anesthetized by inhalation of
isofluorane, and viruses in a volume of 25 ml PBS were
administered into mouse nostrils. Mouse body weight and survival
were monitored daily. Groups of infected mice were sacrificed at
day 4 post-infection to determine mouse lung virus loads. Lung
virus titers were determined as previously described [31].
Antibody responses
The influenza virus-specific serum antibody endpoint titers,
including serum IgG and subtypes (IgG1, G2a, G2b and IgG3)
and mucosal secretory IgA (sIgA) and IgG, were determined by
enzyme-linked immunosorbent assay (ELISA) as described
previously [31,39]. In brief, 96-well microtiter plates (Maxisorp
immunoplate; Nunc Life technologies, Basel, Switzerland) were
coated with 100 ml/well of inactivated PR8 virus (5 mg/ml) in
coating buffer (0.1 M sodium carbonate, pH 9.5) at 4uC
overnight. For serum IgG titers to the heterologous Philippines
H3N2 virus, plates were coated with 100 ml/well of inactivated
virus (5 mg/ml in coating buffer). The serum or mucosal samples
were serially diluted two-fold stepwise and 100 ml were added to
wells. Horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG, IgG1, IgG2a, IgG2b or IgG3 antibodies (Southern
Biotechnology) were used for the determination of serum IgG,
IgG1, IgG2a, IgG2b or IgG3 titers, and HRP-conjugated goat
anti-mouse IgA or IgG antibodies were used for mucosal IgA or
IgG titers. Color was developed using the substrate TMB (Zymed
Invitrogen) and the optical density at 450 nm was read using an
ELISA reader (Bio-Rad). The highest dilution which gave an
OD450 twice that of the naı ¨ve group at the lowest dilution was
designated as the antibody endpoint titer.
Virus neutralization and hemagglutination-inhibition (HI)
assays
Neutralization was performed using MDCK cells as previous
described [31]. Hemagglutination inhibition assays were carried
out as described [45] with modifications: 8 hemagglutination units
of PR8 or Philippines viruses were mixed with serially diluted
receptor-destroying enzyme-pretreated serum samples in a volume
of 50 ml and incubated at 37uC for 1 h. An equal volume of
chicken blood cells (0.5%) was added and incubated at 25uC for
30 min. The HI titer is the reciprocal of the highest dilution that
inhibits hemagglutitation.
Cytokine ELISpot assays
Interferon gamma (INF-c) and interleukin 4 (IL-4) secretion
from immunized mouse splenocytes were evaluated using ELISpot
kits (eBioscience, San Diego, CA) according to the manufacturer’s
instructions. Splenocytes (1610
6 cells) isolated from immunized
mice were seeded into 96-well filtration plate (MultiScreen
TM-HA,
Millipore) precoated with anti-mouse INF- c or IL-4 antibodies
provided in kits. Cells were stimulated with a mixture of two major
histocompatibility complex I (MHC-I) PR8 HA peptides (IYST-
VASSL and LYEKVKSQL), a pool of five MHC-II PR8 HA
peptides (SFERFEIFPKE, HNTNGVTAACSH, CPKYVR-
SAKLRM, KLKNSYVNKKGK, and NAYVSVVTSKYN), or
inactivated PR8 at a concentration of 10 mg/ml. Because
differentiated CD4+Th1 cells recognize antigens presented by
MHC I, and consequentially produce Th1 cytokines (INF- c TNF-
b), these cytokines activate cell-mediated immune reactions
including cytotoxic reactions executed by CD8+T cells. Thus
CD8+T cell responses is a consequence of CD4+Th1 activation
and consistent with the later.
Statistical analysis
Comparisons of multiple treatments among vaccinated groups
were performed using a non-matching two-way ANOVA followed
by Bonferroni’s post test (for Fig. 1 and 6). Comparisons of single
treatment among vaccinated groups were performed using a non-
parametric one-way ANOVA followed by Bonferroni’s multiple
comparison post test (for Fig. 2, 3, 5 and 8). Comparison of
survival curves were performed using the Log-rank (Mantel-Cox)
test (Fig.7A and C). The analyses were done by using GraphPad
Prism version 5.00 for Windows (GraphPad Software, San Diego
California USA). P values of less than 0.05 (p,0.05) were
considered to be statistically significant. P,0.05(*), P,0.01(**),
P,0.001(***), P.0.05(n.s.).
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